43 research outputs found

    Cytokine Signature in Schnitzler Syndrome: Proinflammatory Cytokine Production Associated to Th Suppression

    Get PDF
    Background: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by urticarial exanthema, bone and joint alterations, fever and monoclonal IgM gammopathy. Overactivation of the interleukin(IL)-1 system is reported, even though the exact pathophysiological pathways remain unknown. Objective: To determine ex vivo cytokine profiles of Peripheral Blood Mononuclear Cells (PBMCs) from SchS patients prior to treatment and after initiation of anti-IL-1 therapy (anakinra). The sera cytokine profile was studied in parallel. Methods: We collected blood samples from thirty-six untreated or treated SchS. PBMCs were cultured with and without LPS or anti-CD3/CD28. Cytokine levels were evaluated in serum and cell culture supernatants using Luminex technology. Results: Spontaneous TNFα, IL-6, IL-1β, IL-1α, and IL-1RA release by PBMCs of SchS patients were higher than in controls. LPS-stimulation further induced the secretion of these cytokines. In contrast, after T-cell stimulation, TNFα, IL-10, IFNγ, IL-17A, and IL-4 production decreased in SchS patients compared to healthy controls, but less in treated patients. Whereas IL-1β serum level was not detected in most sera, IL-6, IL-10, and TNFα serum levels were higher in patients with SchS and IFNγ and IL-4 levels were lower. Of note, IL-6 decreased after treatment in SchS (p = 0.04). Conclusion: Our data strengthen the hypothesis of myeloid inflammation in SchS, mediated in particular by IL-1β, TNFα, and IL-6, associated with overproduction of the inhibitors IL-1RA and IL-10. In contrast, we observed a loss of Th1, Th2, and Th17 cell functionalities that tends to be reversed by anakinra

    Progress of the CHARA/SPICA project

    Get PDF
    This is the final version. Available from SPIE via the DOI in this recordSPIE Astronomical Telescopes + Instrumentation conference, 14 - 18 December 2020, Online OnlyCHARA/SPICA (Stellar Parameters and Images with a Cophased Array) is currently being developed at Observatoire de la Cote d'Azur. It will be installed at the visible focus of the CHARA Array by the end of 2021. It has been designed to perform a large survey of fundamental stellar parameters with, in the possible cases, a detailed imaging of the surface or environment of stars. To reach the required precision and sensitivity, CHARA/SPICA combines a low spectral resolution mode R = 140 in the visible and single-mode fibers fed by the AO stages of CHARA. This setup generates additional needs before the interferometric combination: the compensation of atmospheric refraction and longitudinal dispersion, and the fringe stabilization. In this paper, we present the main features of the 6-telescopes fibered visible beam combiner (SPICA-VIS) together with the first laboratory and on-sky results of the fringe tracker (SPICA-FT). We describe also the new fringe-tracker simulator developed in parallel to SPICA-FT.National Science Foundation (NSF)GSU College of Arts and SciencesGSU Office of the Vice President for Research and Economic DevelopmentEuropean Union Horizon 2020Onera’s Direction Scientifique General

    HARMONI at ELT: overview of the capabilities and expected performance of the ELT's first light, adaptive optics assisted integral field spectrograph.

    Get PDF

    Spinal Block with Lignocaine and Fentanyl for Ender Nailing in the Elderly

    No full text

    Book Reviews

    No full text

    IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases

    No full text
    IL-6, soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) levels were measured in sera and pleural effusions from 42 patients with metastatic carcinoma, non-Hodgkin's lymphoma, tuberculosis, cardiac failure and miscellaneous diseases. Pleural IL-6 levels measured by ELISA were very high in all patient groups (mean 34.8 ± 15.3 ng/ml) without significant difference according to diseases. IL-6 was shown to be biologically active in a proliferative assay. Serum IL-6 levels were low (0.049 ± 0.014 ng/ml) and did not correlate with pleural fluid levels. Pleural IL-6 levels correlated with the number of polymorphonuclear cells in pleural fluid (P< 0.03). Pleural sIL-6R levels (76 ± 8 ng/ml) were always lower than serum levels (196 ± 12 ng/ml; P< 0.0001) but correlated with them (P< 0.01). Pleural sIL-6R and albumin levels correlated (P< 0.01), suggesting a transudation of sIL-6R from the serum. Pleural sgp130 levels (10.9 ± 1.0 ng/ml) were lower than serum levels (24.6 ± 2.8 ng/ml; P< 0.002). After gel filtration of pleural fluid, the bulk of IL-6 (>90%) was recovered in a 15 000–30 000 fraction, corresponding to the expected mol. wt of free IL-6. These results suggest a production and a sequestration of IL-6 in the pleural cavity in all studied conditions
    corecore